%0 Journal Article
%T Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
%J -
%D 2019
%R https://doi.org/10.1038/s41416-019-0443-4
%X Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of gemcitabine and oxaliplatin (GEMOX) to sorafenib in aHCC patients
%U https://www.nature.com/articles/s41416-019-0443-4